KYMR: Canaccord Genuity Raises PT
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics with a Buy and raises the price target from $106 to $129
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $106 to $129.